Scancell Holdings PLC - Unquoted

Scancell is a Nottingham-based company that is developing a pipeline of drugs to target various types of cancer. These products are derived from Scancell's proprietary ImmunoBody technology. The first trial being undertaken is for a treatment for melanoma, with a Phase I trial scheduled having started in the UK during Q2 2010.

During 2006, the company sold its pipeline of antibodies to Peptech Ltd, an Australian biotechnology company, in a deal that had a total value of up to �4.85 million.

More detail can be accessed by clicking on Scancell on SMARTCO Research under Links in the right hand column.

Also under Links is a link to the website for Dendreon, which is pursuing a similar scientific approach to Scancell but is taking a different approach to the way in which the treatment is provided.

 

Links:
Dendreon
Proactive Investors
Scancell
Scancell on SMARTCO Research

Last Updated: 24/07/2018

Investment Information:
date of first inv: Dec 2003
cost: £801,000
valn at: 30/06/2018 £1,631,000
equity held: 3.42%